Internal Reference Number: FOI_8288
Date Request Received: 14/11/2024 00:00:00
Date Request Replied To: 17/12/2024 00:00:00
This response was sent via: By Email
Request Summary: Oncology Supplemental
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq) <5 • Durvalumab (Imfinzi) 0 • Nivolumab (Opdivo) 0 • Pembrolizumab (Keytruda) <5 • Chemotherapy 7 • Radiotherapy - unable to answer as Radiotherapy is not provided at SFT. • Chemotherapy AND Radiotherapy - unable to answer as Radiotherapy is not provided at SFT. • Osimertinib <5 | |
| Question Number 2: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only • Zolbetuximab (Vyloy) | |
| Answer To Question 2: • CAPOX (Capecitabine with Oxaliplatin) 0 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <5 • Lonsurf (Trifluridine - tipiracil) 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5 • Any other systemic anti-cancer therapy < 5 • Palliative care only - unable to answer this. • Zolbetuximab (Vyloy) 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
